FTI Portfolio Company Shinobi Therapeutics Expands Leadership Team

December 18, 2024

SONIRE Therapeutics Receives FDA Breakthrough Device Designation for HIFU Pancreatic Cancer Treatment

October 10, 2024

AIRNA Raised Oversubscribed Financing to Advance RNA Editing Therapeutics

August 21, 2024

AbbVie Acquires Celsius Therapeutics

June 27, 2024

Alivexis and Melodia Therapeutics Join Forces to Advance Innovative Therapies

June 24, 2024

Medii Raises Series A Funding to Enhance “E-Consult,” An Exclusive Online Consultation Service for Physicians

March 15, 2024

Fast Track Initiative (FTI) invests in Shinobi Therapeutics, a U.S. and Japan-based company developing hypoimmune iPS cell therapy

December 12, 2023

Global Vascular Secures Series A Funding to Advance Innovative Nanotechnology for Peripheral Artery Disease Treatment

December 5, 2023

Two of FTI’s portfolios receive significant nondilutive funding from AMED to support their pipeline development

December 1, 2023

Fast Track Initiative Invests in CellFiber, Pioneering Cell Mass Production Technology

November 9, 2023

AIRNA Launches to Develop RNA Editing Therapeutics for Rare and Common Diseases

September 19, 2023

Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease

August 3, 2023

Fast Track Initiative Signs Alliance Agreement With AN Venture Partners

June 8, 2023

Koji Yasuda Has Been Appointed as Principal of Fast Track Initiative at Its Boston Office

June 7, 2023

Tai Harada Has Been Appointed as Partner at Fast Track Initiative

June 2, 2023